<DOC>
	<DOCNO>NCT00006229</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether paclitaxel carboplatin effective without BMS-275291 non-small cell lung cancer . PURPOSE : Randomized phase II/III trial compare effectiveness paclitaxel carboplatin without BMS-275291 treat patient advanced metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>Paclitaxel Carboplatin With Without BMS-275291 Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient advance metastatic non-small cell lung cancer treat paclitaxel carboplatin without BMS-275291 . - Compare incidence grade 2 high drug relate arthritis , arthralgia and/or myalgia patient treat regimen . ( Phase II ) - Compare objective tumor response rate , time response , response duration patient treat regimen . - Compare nature , severity , frequency toxic effect regimens patient . - Compare progression free survival patient treat regimen . ( Phase III ) - Correlate expression serum/plasma tissue matrix metalloproteinases ( MMP ) level marker outcome response patient treat regimen . - Compare quality life patient treat regimen . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients stratify accord center , disease stage ( IIIB v IV ) , ECOG performance status ( 0-1 v 2 ) . Patients randomize one two treatment arm . - Arm I : Patients receive paclitaxel IV 3 hour carboplatin IV 30 minute day 1 plus oral BMS-275291 daily day 1-21 . - Arm II : Patients receive paclitaxel carboplatin arm I plus oral placebo daily day 1-21 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . BMS-275291 placebo continue beyond 8 course absence disease progression . Quality life assess . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 776 patient accrue study within 27 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIIB IV nonsmall cell lung cancer ( NSCLC ) Local metastatic failure surgery and/or radiotherapy allow Phase II : At least one measurable lesion At least 20 mm conventional technique OR 10 mm spiral CT scan No known CNS metastases unless asymptomatic least 4 week since prior corticosteroid therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ALT great 2 time ULN ( 5 time ULN liver metastasis ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No significant cardiac disease No uncontrolled high blood pressure , unstable angina , congestive heart failure , second third degree atrioventricular conduction defect , ventricular arrhythmia require medication No myocardial infarction within past year Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction drug contain Cremophor EL No serious active infection underlie medical condition would preclude study participation No peripheral neuropathy No condition ( e.g. , psychological , geographical ) would preclude study participation No prior breast cancer melanoma No prior malignancy within past 5 year except carcinoma situ , basal cell squamous cell skin cancer , cancer curatively treat surgically PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy No prior biological response modifier No concurrent biologic therapy immunotherapy Chemotherapy : No prior antineoplastic chemotherapy , include intrapleural chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics No prior radiotherapy study lesion ( unless evidence disease progression ) 30 % great marrow bearing bone At least 1 week since prior radiotherapy recover No concurrent radiotherapy Surgery : See Disease Characteristics At least 2 week since prior major surgery No concurrent surgery Other : At least 2 week since prior investigational drug No concurrent cytotoxic anticancer therapy No investigational drug 30 day study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>